Asia Pacific PARP Inhibitor Biomarkers Market

Asia Pacific PARP Inhibitor Biomarkers Market Size, Share & Trends Analysis Report By Product (Kits, and Assays), By Application, By Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others), By Country and Growth Forecast, 2024 - 2031

Report Id: KBV-22828 Publication Date: May-2024 Number of Pages: 117
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support

Analysis of Market Size & Trends

The Asia Pacific PARP Inhibitor Biomarkers Market would witness market growth of 8.9% CAGR during the forecast period (2024-2031).

The China market dominated the Asia Pacific PARP Inhibitor Biomarkers Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $109.1 Million by 2031. The Japan market is registering a CAGR of 8.2% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 9.6% during (2024 - 2031).

Asia Pacific PARP Inhibitor Biomarkers Market

The adoption of this in clinical practice and research settings has been steadily increasing, driven by several factors that highlight their importance in personalized cancer care and precision medicine. For example, clinical practice guidelines from reputable organizations, such as the National Comprehensive Cancer Network (NCCN).

Additionally, the market is witnessing several notable trends that reflect the evolving landscape of precision oncology and personalized cancer care. These trends encompass advancements in biomarker discovery, technological innovations in biomarker testing, shifts in clinical practice guidelines, and the emergence of novel therapeutic strategies.

As the hospital sector in India expands, there is increased access to healthcare services, including diagnostic facilities and specialized testing laboratories. This expansion facilitates greater access to biomarker testing services, including it, for patients nationwide. Patients visiting hospitals for cancer treatment may undergo biomarker testing to determine their eligibility for targeted therapies such as these, leading to increased demand for biomarker testing services.

Free Valuable Insights: The Global PARP Inhibitor Biomarkers Market is Predict to reach USD 1.6 Billion by 2031, at a CAGR of 8.3%

Based on Product, the market is segmented into Kits, and Assays. Based on Application, the market is segmented into Breast Cancer, Ovarian Cancer, and Others. Based on Services, the market is segmented into BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others.Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now

List of Key Companies Profiled

  • Myriad Genetics, Inc.
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • NeoGenomics Laboratories
  • Qiagen N.V
  • Agilent Technologies, Inc.
  • Merck KGaA
  • Bayer AG
  • AstraZeneca PLC
  • GlaxoSmithKline PLC (GSK)

Asia Pacific PARP Inhibitor Biomarkers Market Report Segmentation

By Product

  • Kits
  • Assays

By Application

  • Breast Cancer
  • Ovarian Cancer
  • Others

By Services

  • BRCA 1 & 2 Testing
  • HRD Testing
  • HRR Testing
  • Others

By Country

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
HAVE A QUESTION?

HAVE A QUESTION?

Call: +1(646) 600-5072

SPECIAL PRICING & DISCOUNTS


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings


  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo